Dr. Albert Pochen Lin, MD

Dr. Lin practices at Memorial Hermann Surgery Center Southwest LLP - HOPD in Houston, Texas.

Dr. Lin's NPI, 1891734117, was assigned on June 5, 2006. Dr. Lin graduated from David Geffen School of Medicine at UCLA in 2002. Dr. Lin's Texas license number on file is N5193.

Dr. Lin's primary practice is Memorial Hermann Surgery Center Southwest LLP - HOPD, at 7789 Southwest Fwy, Houston, TX 77074.

Dr. Lin's primary practice is Memorial Hermann Surgery Center Southwest LLP - HOPD in Houston, Texas. Dmand AI also links Dr. Lin to 1 physician office and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lin is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lin's licenses on file in 2 states: Texas and Pennsylvania.

Dmand AI lists cataract, cataract surgery with lens implant, eye infection or inflammation, eyelid inflammation, glaucoma, glaucoma surgery, inflammation of iris and secondary membranaous cataract surgery among the conditions Dr. Lin treats.

CMS data shows 900 Medicare services from Dr. Lin across 12 procedure codes in 2024, for 322 Medicare patients. Medicare paid $61,748 for them.

CMS counts 322 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 162 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 8% are also on Medicaid. Their average risk score is 0.95, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 72, with 53% women.

In 2024, Dr. Lin wrote 1,980 Medicare Part D claims for 440 patients. 62% of them were for generic drugs. CMS names the drug for 1,890 of them, across 22 drugs with 11 or more claims each, at $122,988 in total drug cost. In 2023, CMS named 1,898 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lin for performance year 2024, reported individually. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 48 procedures of cataract surgery by Dr. Lin, more than 62% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Lin in 2010. The most frequent topics are Glaucoma, Clinical Competence and Glaucoma, Open-Angle. Dr. Lin has published most often in J Glaucoma. Dr. Lin's most frequent co-authors are Silvia D. Orengo-Nania, MD, Ursula K. Braun, MD, MPH and Peter Tae-Jin Chang, MD.

CMS Open Payments shows 17 general payments to Dr. Lin from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Alcon Laboratories Inc paid the most, $779.

Dr. Lin graduated from David Geffen School of Medicine at UCLA in 2002.

Dr. Lin is in network with 23 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.